InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by Cohen Neil Harris, Director. Director active across 1 company, notably Chemomab Therapeutics Ltd.. In total, 4 reports have been recorded. Split: 4 buys · 0 sell. Total volume traded: €40k. Activity tracked since 6 December 2021. The latest transaction was filed on 18 May 2022 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations4 total
2,000 shares@ US$3.190.051% mcap15.2% of flowAmerican Depositary SharesSEC:0001178913-22-002093:0
Ideal exit: 12 Feb 2023 (T+270)
2,000 shares@ US$4.200.065% mcap19.2% of flowAmerican Depositary SharesSEC:0001178913-22-001117:0
Ideal exit: 9 Dec 2022 (T+270)
2,000 shares@ US$7.43100.0% of flowAmerican Depositary SharesSEC:0001178913-21-003807
Ideal exit: 2 Sept 2022 (T+270)
2,000 shares@ US$7.430.11% mcap32.8% of flowAmerican Depositary SharesSEC:0001178913-21-003807:0
Ideal exit: 2 Sept 2022 (T+270)
4 of 4 declarations
About Cohen Neil Harris
Neil Harris Cohen is a Director of Chemomab Therapeutics Ltd. In this role, he participates in the governance of the company and strategic decision-making. His experience in the biopharmaceutical sector is an asset for the organization.
